{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:47:01Z","timestamp":1791996421702,"version":"4.4.0"},"reference-count":16,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Oncol"],"abstract":"<jats:p>Introduction: The role of nab-paclitaxel in non-small cell lung cancer (NSCLC) as long-term continuation therapy remains underexplored, particularly in combination with anti-angiogenic agents and immunotherapy. We present 2 cases of advanced NSCLC achieving prolonged progression-free survival with nab-paclitaxel-based regimens. Case presentation: Case 1 (ALK-positive) received nab-paclitaxel + bevacizumab every 4 weeks for more than 48 months. Case 2 (driver-negative) received nab-paclitaxel + bevacizumab + toripalimab every 6\u20138 weeks for 24 months. Both patients maintained partial regression of disease, minimal toxicity (no grade, \u22653 adverse events), and preserved quality of life. Conclusion: The literature review highlights synergistic mechanisms of chemotherapy, anti-angiogenesis, and immunotherapy, supported by trials such as IMpower150 and KEYNOTE-407. Low-dose, extended-interval nab-paclitaxel combined with anti-angiogenesis and immunotherapy may offer a feasible maintenance strategy, warranting validation in prospective trials.<\/jats:p>","DOI":"10.1159\/000551998","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:08:23Z","timestamp":1786637303000},"page":"1732-1739","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Continuation Therapy with Nab-Paclitaxel and Bevacizumab \u00b1 Anti-PD-1 in Advanced Non-Small Cell Lung Cancer: Case Reports and Mechanistic Insights"],"prefix":"10.1159","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2621-0851","authenticated-orcid":false,"given":"Xiaofen","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiehao","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.12.057"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae044"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.5848"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01076-8"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108108"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2204.0023"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.24-00172"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae168"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_1982_22"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-02605-8"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0617-6"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.151078"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000163"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.01.007"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1101\/2024.12.29.630658"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.009"}],"container-title":["Case Reports in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000551998","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:02:21Z","timestamp":1791993741000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000551998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000551998","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.33236403","asserted-by":"subject"}]},"ISSN":["1662-6575"],"issn-type":[{"value":"1662-6575","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}